Fuchs Endothelial Corneal Dystrophy (FECD) Market Share Analysis, Growth Opportunities, Current Treatment Practices, Emerging Therapies, Epidemiology, and Key Companies

“Fuchs Endothelial Corneal Dystrophy (FECD) Market”

DelveInsight’s “Fuchs Endothelial Corneal Dystrophy (FECD) Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Fuchs Endothelial Corneal Dystrophy Market trends in the seven major markets (7MM) (i.e., the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Key Highlights from the Fuchs Endothelial Corneal Dystrophy (FECD) Market Report

• An increase in the Fuchs Endothelial Corneal Dystrophy market size is anticipated for the study period, 2019–2032, owing to the expected approval of emerging therapies, improved understanding, and growing awareness of FECD in the 7MM.
• The total Fuchs Endothelial Corneal Dystrophy prevalence in the 7MM was estimated to be approximately 17,499,877 cases in the year 2021, which are expected to increase by 2032.
• In 2021, among the 7MM, the US had the highest total prevalent cases of Fuchs Endothelial Corneal Dystrophy with about 6,450,491 cases, while Spain had the lowest cases in 2021.
• Some of the key companies proactively working in the Fuchs Endothelial Corneal Dystrophy therapeutic market include Kowa Pharmaceutical, Trefoil Therapeutics, Emmecell, Santen, and many more.

Learn more about the key trends and developments driving the market growth @ Fuchs Endothelial Corneal Dystrophy Market Landscape 

Fuchs Endothelial Corneal Dystrophy (FECD) Overview

Fuchs Endothelial Corneal Dystrophy is the defect in the eye’s cornea where endothelial cells degenerate or get damaged. These are sporadic or inherited in an auto-dominant manner. It is characterized by the swelling of the cornea, progressive loss of corneal endothelial cells, thickening of the Descemet’s membrane, and deposition of extracellular matrix in the form of guttae. Swelling of the cornea leads to glare, halo, and reduced visual acuity, eventually leading to corneal blindness.

Descemet’s Stripping Only (DSO) –  DWEK is the latest surgical option for some patients with Fuchs, in which the ophthalmologist carefully strips away a 4 mm circle of central diseased endothelial cells without placing any donor cornea tissue. If the surgery succeeds, healthy endothelial cells from the intact periphery will migrate centrally, covering the defect and providing good quality vision. 

Fuchs Endothelial Corneal Dystrophy (FECD) Epidemiology Segmentation

The Fuchs Endothelial Corneal Dystrophy proffers epidemiological analysis for the study period 2019-32 in the 7MM segmented into:

• Fuchs Endothelial Corneal Dystrophy Total prevalent cases
• Fuchs Endothelial Corneal Dystrophy Total gender-specific cases 
• Fuchs Endothelial Corneal Dystrophy Total age-specific cases 

Download the Fuchs Endothelial Corneal Dystrophy market report to understand which factors are influencing epidemiology trends @ Fuchs Endothelial Corneal Dystrophy Epidemiological Insights

Fuchs Endothelial Corneal Dystrophy (FECD) Market

There are no FDA-approved pharmacological therapies available for FECD. If one has a severe form of the disease, minimally invasive lamellar endothelial keratoplasty (EK) procedures can be used.

Currently, various new therapies are being developed to address the unmet need and to provide certain therapy in the initial stages of the disease. Some of the most prominent ones include Ripasudil (K-321), TTHX1114, EO2002, and STN1010904/AE-001. The launch of emerging therapies is expected to transform the treatment scenario in the coming years.

To learn more about the development in the Fuchs Endothelial Corneal Dystrophy therapeutics market @ Fuchs Endothelial Corneal Dystrophy Market Analysis

Fuchs Endothelial Corneal Dystrophy (FECD) Market Drivers 

• Development of novel pharmacological adjuncts 
• Development of gene therapies 
• Progressive use of less invasive therapy
• DSO improved diagnostics

Fuchs Endothelial Corneal Dystrophy (FECD) Therapeutics Assessment

The FECD pipeline is robust with various drugs at different stages of development expected to launch in the coming years. Some of the key therapies under development include.

• Ripasudil (K-321): Kowa Pharmaceuticals
• TTHX1114: Trefoil Therapeutics
• EO2002: Emmecell
• STN1010904/AE-001: Santen Pharmaceutical/ ActualEyes Inc

And many others

Discover more about therapies set to grab major market share @  Fuch’s Endothelial Dystrophy Market therapeutics outlook

 Scope of the Fuch’s Endothelial Dystrophy (FECD) Market Report:

• Study Period: 2019-32
• Coverage: The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan
• Key Companies in the Fuchs Endothelial Dystrophy Market: Kowa Pharmaceutical, Trefoil Therapeutics, Santen Pharmaceutical Emmecell, and others.
• Therapeutic Assessment: Fuchs Endothelial Corneal Dystrophy off-label and emerging therapies
• Fuchs Endothelial Corneal Dystrophy Market Dynamics: arket drivers and barriers 
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies.

Get in touch with our Business executive @ Fuchs Endothelial Corneal Dystrophy Market Landscape Analysis 

Table of Contents

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/